Copyright © 2011 Arthur J. Chu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. B. Østerud and E. Bjørklid, “Sources of tissue factor,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 11–23, 2006.
2. N. S. Key and N. MacKman, “Tissue factor and its measurement in whole blood, plasma, and microparticles,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 8, pp. 865–875, 2010. View at Publisher · View at Google Scholar · View at PubMed
3. L. C. Petersen, S. Valentin, and U. Hedner, “Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor,” Thrombosis Research, vol. 79, no. 1, pp. 1–47, 1995. View at Publisher · View at Google Scholar
4. A. J. Chu, “Tissue factor mediates inflammation,” Archives of Biochemistry and Biophysics, vol. 440, no. 2, pp. 123–132, 2005.
5. B. Szotowski, S. Antoniak, W. Poller, H. P. Schultheiss, and U. Rauch, “Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines,” Circulation Research, vol. 96, no. 12, pp. 1233–1239, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. F. S. Kittur, C. Manithody, J. H. Morrissey, and A. R. Rezaie, “The cofactor function of the N-terminal domain of tissue factor,” Journal of Biological Chemistry, vol. 279, no. 38, pp. 39745–39749, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. J. Ahamed, F. Niessen, T. Kurokawa et al., “Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia,” Blood, vol. 109, no. 12, pp. 5251–5259, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. L. Sharma, E. Melis, M. J. Hickey et al., “The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia,” American Journal of Pathology, vol. 165, no. 1, pp. 331–340, 2004. View at Scopus
9. A. J. Chu, “Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications,” Cell Biochemistry and Function, vol. 24, no. 2, pp. 173–192, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. B. Furie and B. C. Furie, “Mechanisms of thrombus formation,” The New England Journal of Medicine, vol. 359, no. 9, pp. 938–949, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. J. Cho, B. C. Furie, S. R. Coughlin, and B. Furie, “A critical role for extracellular protein disulfide isomerase during thrombus formation in mice,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 1123–1131, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. C. Reinhardt, M. L. von Brühl, D. Manukyan et al., “Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 1110–1122, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. A. Breitenstein, S. Stein, E. W. Holy et al., “Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells,” Cardiovascular Research, vol. 89, no. 2, pp. 464–472, 2011. View at Publisher · View at Google Scholar · View at PubMed
14. R. Dardik, D. Varon, I. Tamarin et al., “Homocysteine and oxidized low density lipoprotein enhance platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation,” Journal of Thrombosis and Haemostasis, vol. 83, no. 2, pp. 338–344, 2000. View at Scopus
15. H. Hölschermann, H. M. Terhalle, U. Zakel et al., “Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives,” Journal of Thrombosis and Haemostasis, vol. 82, no. 6, pp. 1614–1620, 1999. View at Scopus
16. M. C. Lin, F. Almus-Jacobs, H. H. Chen et al., “Shear stress induction of the tissue factor gene,” Journal of Clinical Investigation, vol. 99, no. 4, pp. 737–744, 1997. View at Scopus
17. H. Cai, C. Song, I. Endoh et al., “Serum amyloid A induces monocyte tissue factor,” Journal of Immunology, vol. 178, no. 3, pp. 1852–1860, 2007. View at Scopus
18. J. Steffel, C. Arnet, A. Akhmedov, S. M. Iseli, T. F. Lüscher, and F. C. Tanner, “Histamine differentially interacts with tumor necrosis factor-α and thrombin in endothelial tissue factor induction: the role of c-Jun NH₂-terminal kinase,” Journal of Thrombosis and Haemostasis, vol. 4, no. 11, pp. 2452–2460, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. S. Matetzky, S. Tani, S. Kangavari et al., “Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity,” Circulation, vol. 102, no. 6, pp. 602–604, 2000. View at Scopus
20. P. Cirillo, S. De Rosa, M. Pacileo et al., “Nicotine induces tissue factor expression in cultured endothelial and smooth muscle cells,” Journal of journal of Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 453–458, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. K. P. Henrikson, J. A. Greenwood, B. T. Pentecost, E. E. Jazin, and H. W. Dickerman, “Estrogen control of uterine tissue factor messenger ribonucleic acid levels,” Endocrinology, vol. 130, no. 5, pp. 2669–2674, 1992. View at Publisher · View at Google Scholar · View at Scopus
22. A. Iakhiaev, U. Pendurthi, and S. Idell, “Asbestos induces tissue factor in Beas-2B human lung bronchial epithelial cells in vitro,” Lung, vol. 182, no. 4, pp. 251–264, 2004. View at Publisher · View at Google Scholar · View at Scopus
23. H. Kawano, H. Tsuji, H. Nishimura et al., “Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells,” Blood, vol. 97, no. 6, pp. 1697–1702, 2001. View at Publisher · View at Google Scholar · View at Scopus
24. K. V. Reddy, G. Bhattacharjee, G. Schabbauer et al., “Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability,” Journal of Leukocyte Biology, vol. 76, no. 1, pp. 145–151, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
25. Y. Cadroy, D. Dupouy, and B. Boneu, “Arachidonic acid enhances the tissue factor expression of mononuclear cells by the cyclo-oxygenase-1 pathway: beneficial effect of n-3 fatty acids,” Journal of Immunology, vol. 160, no. 12, pp. 6145–6150, 1998. View at Scopus
26. D. Corseaux, T. Meurice, I. Six et al., “Basic fibroblast growth factor increases tissue factor expression in circulating monocytes and in vascular wall,” Circulation, vol. 101, no. 16, pp. 2000–2006, 2000. View at Scopus
27. A. L. Armesilla, E. Lorenzo, P. Gómez del Arco, S. Martínez-Martínez, A. Alfranca, and J. M. Redondo, “Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 2032–2043, 1999. View at Scopus
28. S. Kato, M. Pinto, A. Carvajal et al., “Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells,” Journal of Thrombosis and Haemostasis, vol. 94, no. 2, pp. 444–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
29. S. Camino-López, L. Badimon, A. González, D. Canals, E. Peña, and V. Llorente-Cortés, “Aggregated low density lipoprotein induces tissue factor by inhibiting sphingomyelinase activity in human vascular smooth muscle cells,” Journal of Thrombosis and Haemostasis, vol. 7, no. 12, pp. 2137–2146, 2009. View at Scopus
30. S. Rafail, K. Ritis, K. Schaefer et al., “Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNFα involvement,” Thrombosis Research, vol. 122, no. 3, pp. 366–375, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. S. Shetty, Y. P. Bhandary, S. K. Shetty et al., “Induction of tissue factor by urokinase in lung epithelial cells and in the lungs,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 12, pp. 1355–1366, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. H. Takeya, E. C. Gabazza, S. Aoki, H. Ueno, and K. Suzuki, “Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells,” Blood, vol. 102, no. 5, pp. 1693–1700, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. J. L. Wei, H. M. Cui, and C. Y. Ma, “Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome,” European Journal of Medical Research, vol. 12, no. 5, pp. 216–221, 2007. View at Scopus
34. S. Steiner, W. S. Speidl, J. Pleiner et al., “Simvastatin blunts endotoxin-induced tissue factor in vivo,” Circulation, vol. 111, no. 14, pp. 1841–1846, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. J. Steffel, M. Hermann, H. Greutert et al., “Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH₂ kinase phosphorylation,” Circulation, vol. 111, no. 13, pp. 1685–1689, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. Y. Kunieda, K. Nakagawa, H. Nishimura et al., “HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells,” Thrombosis Research, vol. 110, no. 4, pp. 277–234, 2003. View at Publisher · View at Google Scholar · View at Scopus
37. H. Y. Wang, Y. M. Yang, Y. Zhuang, H. N. Chen, Y. L. Wan, and Y. T. Huang, “The effect of celecoxib on tissue factor expression in pancreatic cancer cells,” Chinese Medical Journal, vol. 120, no. 20, pp. 1753–1756, 2007. View at Scopus
38. E. Napoleone, F. Zurlo, M. C. Latella et al., “Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells,” European Journal of Cancer, vol. 45, no. 3, pp. 470–477, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. B. Engelmann, S. Zieseniss, K. Brand et al., “Tissue factor expression of human monocytes is suppressed by lysophosphatidylcholine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 1, pp. 47–53, 1999. View at Scopus
40. A. J. Gerrits, C. A. Koekman, C. Yildirim, R. Nieuwland, and J. W. N. Akkerman, “Insulin inhibits tissue factor expression in monocytes,” Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 198–205, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. J. S. Ungerstedt, K. Heimersson, T. Söderström, and M. Hansson, “Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression,” Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2554–2560, 2003. View at Scopus
42. M. Gerlach, D. Keh, G. Bezold et al., “Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite,” Intensive Care Medicine, vol. 24, no. 11, pp. 1199–1208, 1998. View at Publisher · View at Google Scholar · View at Scopus
43. N. Maugeri, G. Giordano, M. P. Petrilli et al., “Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?” Journal of Thrombosis and Haemostasis, vol. 4, no. 12, pp. 2593–2598, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. M. A. van Zoelen, K. Bakhtiari, M. C. Dessing et al., “Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells,” Journal of Thrombosis and Haemostasis, vol. 96, no. 6, pp. 789–793, 2006. View at Publisher · View at Google Scholar · View at Scopus
45. G. G. Camici, J. Steffel, A. Akhmedov et al., “Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents,” Circulation, vol. 114, no. 14, pp. 1512–1521, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. E. Napoleone, A. Di Santo, M. Camera, E. Tremoli, and R. Lorenzet, “Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes,” Circulation Research, vol. 86, no. 2, pp. 139–143, 2000. View at Scopus
47. Y. J. Chen, L. Q. Zhang, G. P. Wang et al., “Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 100, no. 2, pp. 291–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
48. T. Saito, T. Koyama, K. Nagata, R. Kamiyama, and S. Hirosawa, “Anticoagulant effects of retinoic acids on leukemia cells,” Blood, vol. 87, no. 2, pp. 657–665, 1996. View at Scopus
49. A. Falanga, M. Marchetti, S. Giovanelli, and T. Barbui, “All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4),” Blood, vol. 87, no. 2, pp. 613–617, 1996. View at Scopus
50. J. Chung, T. Koyama, M. Ohsawa, A. Shibamiya, A. Hoshi, and S. Hirosawa, “1,25(OH)₂D₃ blocks TNF-induced monocytic tissue factor expression by inhibition of transcription factors AP-1 and NF-${}_{\kappa }\text{B}$,” Laboratory Investigation, vol. 87, no. 6, pp. 540–547, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. S. Eligini, C. Banfi, M. Brambilla et al., “15-Deoxy-Δ12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade,” Journal of Thrombosis and Haemostasis, vol. 88, no. 3, pp. 524–532, 2002. View at Scopus
52. B. P. Neve, D. Corseaux, G. Chinetti et al., “PPAR α agonists inhibit tissue factor expression in human monocytes and macrophages,” Circulation, vol. 103, no. 2, pp. 207–212, 2001. View at Scopus
53. N. Marx, N. Mackman, U. Schönbeck et al., “PPAR α activators inhibit tissue factor expression and activity in human monocytes,” Circulation, vol. 103, no. 2, pp. 213–219, 2001. View at Scopus
54. N. Terasaka, A. Hiroshima, A. Ariga et al., “Liver X receptor agonists inhibit tissue factor expression in macrophages,” The FEBS Journal, vol. 272, no. 6, pp. 1546–1556, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. V. Ollivier, C. Ternisien, T. Vu, J. Hakim, and D. de Prost, “Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes,” FEBS Letters, vol. 322, no. 3, pp. 231–234, 1993. View at Publisher · View at Google Scholar · View at Scopus
56. G. Kaur, M. Roberti, F. Raul, and U. R. Pendurthi, “Suppression of human monocyte tissue factor induction by red wine phenolics and synthetic derivatives of resveratrol,” Thrombosis Research, vol. 119, no. 2, pp. 247–256, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. S. Eligini, F. Violi, C. Banfi et al., “Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism,” Cardiovascular Research, vol. 69, no. 1, pp. 218–226, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. A. Breitenstein, S. F. Stämpfli, G. G. Camici et al., “Amiodarone inhibits arterial thrombus formation and tissue factor translation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2231–2238, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. M. Arai, M. Uchiba, H. Komura, Y. Mizuochi, N. Harada, and K. Okajima, “Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 206–213, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. G. Schabbauer, M. Tencati, B. Pedersen, R. Pawlinski, and N. Mackman, “PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1963–1969, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. X. Zhang, H. Yu, J. R. Lou et al., “MicroRNA-₁₉ (miR-₁₉) regulates tissue factor expression in breast cancer cells,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1429–1435, 2011. View at Publisher · View at Google Scholar · View at PubMed
62. J. E. Bluff, M. Amarzguioui, J. Slattery, M. W. Reed, N. J. Brown, and C. A. Staton, “Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo,” Breast Cancer Research and Treatment, vol. 128, no. 3, pp. 691–701, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. E. Cavusoglu, I. Chen, J. Rappaport, and J. D. Marmur, “Inhibition of tissue factor gene induction and activity using a hairpin ribozyme,” Circulation, vol. 105, no. 19, pp. 2282–2287, 2002. View at Publisher · View at Google Scholar · View at Scopus
64. Y. Förster and B. Schwenzer, “Inhibition of TF gene expression by antisense oligonucleotides in different cancer cell lines,” Journal of Experimental Therapeutics and Oncology, vol. 4, no. 4, pp. 281–289, 2004. View at Scopus
65. M. Pinotti, C. Bertolucci, E. Frigato et al., “Suppression of HUVEC tissue factor synthesis by antisense oligodeoxynucleotide,” Thrombosis Research, vol. 122, no. 1, pp. 99–107, 2008. View at Publisher · View at Google Scholar · View at PubMed
66. J. Yin, X. G. Luo, W. J. Yu, J. Y. Liao, Y. J. Shen, and Z. W. Zhang, “Antisense oligodeoxynucleotide against tissue factor inhibits human umbilical vein endothelial cells injury induced by anoxia-reoxygenation,” Cellular Physiology and Biochemistry, vol. 25, no. 4-5, pp. 477–490, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. S. Butenas, T. Orfeo, and K. G. Mann, “Tissue factor activity and function in blood coagulation,” Thrombosis Research, vol. 122, no. 1, pp. S42–S46, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. M. L. Liu, M. P. Reilly, P. Casasanto, S. E. McKenzie, and K. J. Williams, “Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 430–435, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. A. J. Chu, “Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit,” Frontiers in Bioscience, vol. 11, no. 1, pp. 256–271, 2006. View at Publisher · View at Google Scholar · View at Scopus
70. C. A. Kretz, N. Vaezzadeh, and P. L. Gross, “Tissue factor and thrombosis models,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 900–908, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. C. Tapparelli, R. Metternich, and N. S. Cook, “Structure and function of thrombin receptors,” Trends in Pharmacological Sciences, vol. 14, no. 12, pp. 426–428, 1993. View at Publisher · View at Google Scholar · View at Scopus
72. G. Soslau, R. Class, D. A. Morgan et al., “Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib,” Journal of Biological Chemistry, vol. 276, no. 24, pp. 21173–21183, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
73. F. Adam, M. C. Guillin, and M. Jandrot-Perrus, “Glycoprotein Ib-mediated platelet activation: a signalling pathway triggered by thrombin,” European Journal of Biochemistry, vol. 270, no. 14, pp. 2959–2970, 2003. View at Publisher · View at Google Scholar · View at Scopus
74. B. N. Bouma and J. C. Meijers, “New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R),” Seminars in Hematology, vol. 41, no. 1, supplement 1, pp. 13–19, 2004. View at Scopus
75. A. H.C. Guimarães and D. C. Rijken, “Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model,” Journal of Thrombosis and Haemostasis, vol. 91, no. 3, pp. 473–479, 2004.
76. S. Mandl-Weber, B. Haslinger, and T. Sitter, “Thrombin upregulates production of plasminogen activator inhibitor type 1 in human peritoneal mesothelial cells,” Peritoneal Dialysis International, vol. 19, no. 4, pp. 319–324, 1999. View at Scopus
77. B. White and D. Perry, “Acquired antithrombin deficiency in sepsis,” British Journal of Haematology, vol. 112, no. 1, pp. 26–31, 2001. View at Publisher · View at Google Scholar · View at Scopus
78. N. Iversen, F. G. Strekerud, and U. Abildgaard, “Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex,” Blood Coagulation and Fibrinolysis, vol. 11, no. 7, pp. 591–598, 2000. View at Scopus
79. H. Asakura, Y. Ontachi, T. Mizutani et al., “Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation,” European Journal of Haematology, vol. 67, no. 3, pp. 170–175, 2001. View at Publisher · View at Google Scholar · View at Scopus
80. N. Busso, V. Chobaz-Péclat, J. Hamilton, P. Spee, N. Wagtmann, and A. So, “Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation,” Arthritis Research and Therapy, vol. 10, no. 2, article no. R42, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
81. M. Puhlmann, D. M. Weinreich, J. M. Farma, N. M. Carroll, E. M. Turner, and H. R. Alexander Jr., “Interleukin-1β induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity,” Journal of Translational Medicine, vol. 3, article no. 37, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. J. P. Luyendyk, B. P. Sullivan, G. L. Guo, and R. Wang, “Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice,” American Journal of Pathology, vol. 176, no. 1, pp. 177–186, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
83. F. B. Taylor Jr., A. Chang, W. Ruf et al., “Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody,” Circulatory Shock, vol. 33, no. 3, pp. 127–134, 1991. View at Scopus
84. M. A. Cunningham, P. Romas, P. Hutchinson, S. R. Holdsworth, and P. G. Tipping, “Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages,” Blood, vol. 94, no. 10, pp. 3413–3420, 1999. View at Scopus
85. E. Porreca, C. Di Febbo, A. di Castelnuovo et al., “Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients,” Atherosclerosis, vol. 165, no. 1, pp. 159–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
86. H. Xu, V. A. Ploplis, and F. J. Castellino, “A coagulation factor VII deficiency protects against acute inflammatory responses in mice,” Journal of Pathology, vol. 210, no. 4, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
87. E. De Jonge, P. W. Friederich, G. P. Vlasuk et al., “Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects,” Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 3, pp. 495–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
88. E. K. Kruithof, D. Agay, J. C. Mestries, M. P. Gascon, and A. Ythier, “The effect of factor Xa/phospholipid infusion on the acute phase response in baboons,” Journal of Thrombosis and Haemostasis, vol. 77, no. 2, pp. 308–311, 1997. View at Scopus
89. K. McLean, S. Schirm, A. Johns, J. Morser, and D. R. Light, “FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834,” Thrombosis Research, vol. 103, no. 4, pp. 281–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
90. N. H. Senden, T. M. Jeunhomme, J. W. Heemskerk et al., “Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells,” Journal of Immunology, vol. 161, no. 8, pp. 4318–4324, 1998. View at Scopus
91. F. M. Szaba and S. T. Smiley, “Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo,” Blood, vol. 99, no. 3, pp. 1053–1059, 2002. View at Publisher · View at Google Scholar · View at Scopus
92. K. Johnson, Y. Choi, E. DeGroot, I. Samuels, A. Creasey, and L. Aarden, “Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation,” Journal of Immunology, vol. 160, no. 10, pp. 5130–5135, 1998. View at Scopus
93. Y. Hirota, Y. Osuga, O. Yoshino et al., “Possible roles of thrombin-induced activation of protease-activated receptor 1 in human luteinized granulosa cells,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 8, pp. 3952–3957, 2003. View at Publisher · View at Google Scholar · View at Scopus
94. M. Caunt, Y. Q. Huang, P. C. Brooks, and S. Karpatkin, “Thrombin induces neoangiogenesis in the chick chorioallantoic membrane,” Journal of Thrombosis and Haemostasis, vol. 1, no. 10, pp. 2097–2102, 2003. View at Scopus
95. T. Arisato, K. P. Sarker, K. Kawahara et al., “The agonist of the protease-activated receptor-1 (PAR1) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human vascular smooth muscle cells,” Cellular and Molecular Life Sciences, vol. 60, no. 8, pp. 1716–1724, 2003. View at Publisher · View at Google Scholar · View at Scopus
96. G. Kaplanski, V. Marin, M. Fabrigoule et al., “Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM₋₁; CD₅₄) and vascular cell adhesion molecule-1 (VCAM₋₁; CD₁₀₆),” Blood, vol. 92, no. 4, pp. 1259–1267, 1998. View at Scopus
97. A. R. Gear and D. Camerini, “Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense,” Microcirculation, vol. 10, no. 3-4, pp. 335–350, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
98. M. E. Lee, S. M. Kweon, and S. U. Nham, “Fibrin stimulates microfilament reorganization and IL-1β production in human monocytic THP-1 cells,” Molecules and Cells, vol. 11, no. 1, pp. 13–20, 2001. View at Scopus
99. X. Liu and T. H. Piela-Smith, “Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts,” Journal of Immunology, vol. 165, no. 9, pp. 5255–5261, 2000.
100. S. C. Robson, E. G. Shephard, and R. E. Kirsch, “Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro,” British Journal of Haematology, vol. 86, no. 2, pp. 322–326, 1994. View at Scopus
101. M. Hamaguchi, Y. Morishita, I Takahashi, M. Ogura, J. Takamatsu, and H. Saito, “FDP D-dimer induces the secretion of interleukin-1, urokinase-type-plasminogen activator, and plasminiogen activator inhibitor-2 in a human promonocytic leukiemia cell line,” Blood, vol. 77, no. 1, pp. 94–100, 1991.
102. M. Csala, I. Léránt, G. Bánhegyi et al., “Prostaglandin-independent stimulation of interleukin-6 production by fibrinogen degradation product D in perfused murine liver,” Scandinavian Journal of Immunology, vol. 48, no. 3, pp. 269–271, 1998. View at Publisher · View at Google Scholar
103. M. E. Lee, K. J. Rhee, and S. U. Nham, “Fragment E derived from both fibrin fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages,” Molecules and Cells, vol. 9, no. 1, pp. 7–13, 1999. View at Scopus
104. R. C. Chambers and G. J. Laurent, “Coagulation cascade proteases and tissue fibrosis,” Biochemical Society Transactions, vol. 30, no. 2, pp. 194–200, 2002. View at Scopus
105. R. Ramachandran and M. D. Hollenberg, “Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more,” British Journal of Pharmacology, vol. 153, no. 1, pp. S263–S282, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
106. M. Riewald and W. Ruf, “Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 14, pp. 7742–7747, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
107. N. Asokananthan, P. T. Graham, J. Fink et al., “Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E₂ release from human respiratory epithelial cells,” Journal of Immunology, vol. 168, no. 7, pp. 3577–3585, 2002. View at Scopus
108. V. Temkin, B. Kantor, V. Weg, M. L. Hartman, and F. Levi-Schaffer, “Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release,” Journal of Immunology, vol. 169, no. 5, pp. 2662–2669, 2002. View at Scopus
109. Y. Kida, H. Inoue, T. Shimizu, and K. Kuwano, “Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2,” Infection and Immunity, vol. 75, no. 1, pp. 164–174, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
110. E. B. Kelso, W. R. Ferrell, J. C. Lockhart et al., “Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 765–771, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
111. M. S. Kim, H. Jo, J. Y. Um, et al., “Agonists of proteinase-activated receptor 2 induce TNF-α secretion from astrocytoma cells,” Cell Biochemistry and Function, vol. 20, no. 4, pp. 339–345, 2002.
112. R. Ramachandran, A. H. Morice, and S. J. Compton, “Proteinase-activated receptor2 agonists upregulate granulocyte colony-stimulating factor, IL-8, and VCAM-1 expression in human bronchial fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 1, pp. 133–141, 2006. View at Publisher · View at Google Scholar · View at PubMed
113. E. J. Mackie, C. N. Pagel, R. Smith, M. R. de Niese, S. J. Song, and R. N. Pike, “Protease-activated receptors: a means of converting extracellular proteolysis into intracellular signals,” IUBMB Life, vol. 53, no. 6, pp. 277–281, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
114. F.-J. Neumann, I. Ott, N. Marx et al., “Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 12, pp. 3399–3405, 1997.
115. E. K. Kruithof, J. C. Mestries, M.-P. Gascon, and A. Ythier, “The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation—effect of interleukin 6,” Journal of Thrombosis and Haemostasis, vol. 77, no. 5, pp. 905–910, 1997.
116. K. Kambas, M. M. Markiewski, I. A. Pneumatikos et al., “C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome,” Journal of Immunology, vol. 180, no. 11, pp. 7368–7375, 2008. View at Scopus
117. J. Wu, M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn, and W. P. Fay, “C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 4, pp. 698–704, 2008. View at Publisher · View at Google Scholar · View at PubMed
118. J.-S. Kim, D.-W. Park, H.-K. Lee, J.-R. Kim, and S.-H. Baek, “Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway,” Biochemical and Biophysical Research Communications, vol. 390, no. 2, pp. 196–200, 2009. View at Publisher · View at Google Scholar · View at PubMed
119. E. Napoleone, A. di Santo, G. Peri et al., “The long pentraxin PTX₃ up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation,” Journal of Leukocyte Biology, vol. 76, no. 1, pp. 203–209, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
120. C. Gebhard, S. F. Stämpfli, C. E. Gebhard et al., “Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis,” Basic Research in Cardiology, vol. 104, no. 3, pp. 285–294, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
121. E. Camerer, J.-A. Røttingen, E. Gjernes et al., “Coagulation factors VIIa and Xa induce cell signaling leading to up- regulation of the egr-1 gene,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32225–32233, 1999. View at Publisher · View at Google Scholar
122. K. Akahane, K. Okamoto, M. Kikuchi et al., “Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats,” Surgery, vol. 130, no. 5, pp. 809–818, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
123. R. Jiang, N. P. Wang, K. A. Tanaka et al., “Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways,” Journal of Surgical Research, vol. 169, no. 2, pp. 319–327, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
124. D. Chen, K. Riesbeck, J. H. McVey et al., “Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins,” Xenotransplantation, vol. 8, no. 4, pp. 258–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
125. C. Banfi, M. Brioschi, S. Barcella et al., “Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2437–2444, 2007. View at Publisher · View at Google Scholar · View at PubMed
126. F. Langer, C. Morys-Wortmann, B. Küsters, and J. Storck, “Endothelial protease-activated receptor-2 induces tissue factor expression and von Willebrand factor release,” British Journal of Haematology, vol. 105, no. 2, pp. 542–550, 1999.
127. M. Haubitz, M. Gerlach, H. J. Kruse, and R. Brunkhorst, “Endothelial tissue factor stimulation by proteinase 3 and elastase,” Clinical and Experimental Immunology, vol. 126, no. 3, pp. 584–588, 2001. View at Publisher · View at Google Scholar · View at Scopus
128. N. M. Caplice, C. S. Mueske, L. S. Kleppe, and R. D. Simari, “Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity,” Circulation, vol. 98, no. 11, pp. 1051–1057, 1998. View at Scopus
129. A. Hamik, H. Setiadi, G. Bu, R. P. McEver, and J. H. Morrissey, “Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein,” Journal of Biological Chemistry, vol. 274, no. 8, pp. 4962–4969, 1999. View at Publisher · View at Google Scholar · View at Scopus
130. I. Ott, Y. Miyagi, K. Miyazaki et al., “Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 874–882, 2000.
131. D. L. Miller, K. Welty-Wolf, M. S. Carraway et al., “Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide,” American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 6, pp. 650–658, 2002. View at Scopus
132. E. Lindmark and A. Siegbahn, “Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin,” Thrombosis Research, vol. 108, no. 1, pp. 77–84, 2002. View at Publisher · View at Google Scholar · View at Scopus
133. T. Pernerstorfer, U. Hollenstein, J. B. Hansen et al., “Heparin blunts endotoxin-induced coagulation activation,” Circulation, vol. 100, no. 25, pp. 2485–2490, 1999. View at Scopus
134. A. M. Gori, G. Pepe, M. Attanasio et al., “Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration,” Journal of Thrombosis and Haemostasis, vol. 81, no. 4, pp. 589–593, 1999.
135. S. D. Gertz, J. T. Fallon, R. Gallo, et al., “Hirudin reduces tissue factor expression in neointima after ballon injury in rabbit femoral and porcine coronary arteies,” Circulation, vol. 98, pp. 580–587, 1998.
136. H. Hölschermann, R. M. Bohle, H. Schmidt et al., “Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts,” Circulation, vol. 102, no. 3, pp. 357–363, 2000. View at Scopus
137. X. Chen, S. Ren, M. G. Ma et al., “Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-β in carotid artery of atherosclerotic rabbits,” Atherosclerosis, vol. 169, no. 1, pp. 31–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
138. P. J. Souter, S. Thomas, A. R. Hubbard, S. Poole, J. Römisch, and E. Gray, “Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood,” Critical Care Medicine, vol. 29, no. 1, pp. 134–139, 2001. View at Scopus
139. F. Shu, H. Kobayashi, K. Fukudome, N. Tsuneyoshi, M. Kimoto, and T. Terao, “Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner,” FEBS Letters, vol. 477, no. 3, pp. 208–212, 2000. View at Publisher · View at Google Scholar
140. V. V. Sullivan, A. E. Hawley, D. M. Farris et al., “Decrease in fibrin content of venous thrombi in selectin-deficient mice,” Journal of Surgical Research, vol. 109, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
141. P. Libby and D. I. Simon, “Inflammation and thrombosis: the clot thickens,” Circulation, vol. 103, no. 13, pp. 1718–1720, 2001. View at Scopus
142. P. K. Henke, T. W. Wakefield, A. M. Kadell et al., “Interleukin-8 administration enhances venous thrombosis resolution in a rat model,” Journal of Surgical Research, vol. 99, no. 1, pp. 84–91, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
143. M. D. Hollenberg, M. Saifeddine, S. Sandhu, S. Houle, and N. Vergnolle, “Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo,” British Journal of Pharmacology, vol. 143, no. 4, pp. 443–454, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
144. T. Palabrica, R. Lobb, B. C. Furie et al., “Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets,” Nature, vol. 359, no. 6398, pp. 848–851, 1992. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
145. P. Tan, F. W. Luscinskas, and S. Homer-Vanniasinkam, “Cellular and molecular mechanisms of inflammation and thrombosis,” European Journal of Vascular and Endovascular Surgery, vol. 17, no. 5, pp. 373–389, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
146. P. Thanaporn, D. D. Myers, S. K. Wrobleski et al., “P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model,” Surgery, vol. 134, no. 2, pp. 365–371, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
147. J. F. Murphy and J. L. McGregor, “A peptide (P2) derived from the variable heavy chain of an anti-P-selectin monoclonal antibody (LYP20) inhibits leucocyte adhesion to thrombin-activated platelets and endothelial cells,” British Journal of Haematology, vol. 120, no. 4, pp. 605–610, 2003. View at Publisher · View at Google Scholar · View at Scopus
148. C. F. Toombs, G. L. Degraaf, J. P. Martin, J. G. Geng, D. C. Anderson, and R. J. Shebuski, “Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 275, no. 2, pp. 941–949, 1995. View at Scopus
149. T. W. Wakefield, R. M. Strieter, C. A. Wilke et al., “Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 2, pp. 258–268, 1995.
150. M. Hayden, M. Pignone, C. Phillips, and C. Mulrow, “Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive services task force,” Annals of Internal Medicine, vol. 136, no. 2, pp. 161–172, 2002. View at Scopus
151. B. Pitt, C. Penine, and J. T. Willerson, “Cyclooxygenase-2 inhibition and cardiovascular events,” Circulation, vol. 106, no. 2, pp. 167–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
152. P. Cirillo, P. Golino, P. Calabrò et al., “Activated platelets stimulate tissue factor expression in smooth muscle cells,” Thrombosis Research, vol. 112, no. 1-2, pp. 51–57, 2003. View at Publisher · View at Google Scholar · View at PubMed
153. H. Deguchi, H. Takeya, H. Wada et al., “Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes,” Blood, vol. 90, no. 6, pp. 2345–2356, 1997. View at Scopus
154. M. A. Krupiczojc, C. J. Scotton, and R. C. Chambers, “Coagulation signalling following tissue injury: focus on the role of factor Xa,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 6-7, pp. 1228–1237, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
155. S. Danese, A. Papa, S. Saibeni, A. Repici, A. Malesci, and M. Vecchi, “Inflammation and coagulation in inflammatory bowel disease: the clot thickens,” American Journal of Gastroenterology, vol. 102, no. 1, pp. 174–186, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
156. M. Levi, T. van der Poll, and H. Ten Cate, “Tissue factor in infection and severe inflammation,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 33–39, 2006.
157. S. Gando, “Tissue factor in trauma and organ dysfunction,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 48–53, 2006.
158. C. Lupu, A. D. Westmuckett, G. Peer et al., “Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis,” American Journal of Pathology, vol. 167, no. 4, pp. 1161–1172, 2005. View at Scopus
159. M. S. Carraway, K. E. Welty-Wolf, D. L. Miller et al., “Blockade of tissue factor: treatment for organ injury in established sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 9, pp. 1200–1209, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
160. K. Uno, S. Homma, T. Satoh et al., “Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer,” British Journal of Cancer, vol. 96, no. 2, pp. 290–295, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
161. G. Krikun, F. Schatz, H. Taylor, and C. J. Lockwood, “Endometriosis and tissue factor,” Annals of the New York Academy of Sciences, vol. 1127, pp. 101–105, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
162. T. Ueno, M. Toi, M. Koike, S. Nakamura, and T. Tominaga, “Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration,” British Journal of Cancer, vol. 83, no. 2, pp. 164–170, 2000. View at Scopus
163. S. Regina, J. Rollin, C. Bléchet, S. Iochmann, P. Reverdiau, and Y. Gruel, “Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation,” Journal of Thoracic Oncology, vol. 3, no. 7, pp. 689–697, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
164. V. Kaushal, P. Mukunyadzi, E. R. Siegel, R. A. Dennis, D. E. Johnson, and M. Kohli, “Expression of tissue factor in prostate cancer correlates with malignant phenotype,” Applied Immunohistochemistry and Molecular Morphology, vol. 16, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at PubMed
165. A. A. Khorana, S. A. Ahrendt, C. K. Ryan et al., “Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer,” Clinical Cancer Research, vol. 13, no. 10, pp. 2870–2875, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
166. C. Kirszberg, L. G. Lima, A. Da Silva de Oliveira et al., “Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines,” Melanoma Research, vol. 19, no. 5, pp. 301–308, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
167. C. Shigemori, H. Wada, K. Matsumoto, H. Shiku, S. Nakamura, and H. Suzuki, “Tissue factor expression and metastatic potential of colorectal cancer,” Journal of Thrombosis and Haemostasis, vol. 80, no. 6, pp. 894–898, 1998.
168. M. Z. Wojtukiewicz, E. Sierko, L. R. Zacharski, L. Zimnoch, B. Kudryk, and W. Kisiel, “Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer,” Seminars in Thrombosis and Hemostasis, vol. 29, no. 3, pp. 291–299, 2003. View at Publisher · View at Google Scholar · View at PubMed
169. F. S. Ribeiro, T. A. Simão, N. D. Amoêdo et al., “Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer,” Oncology Reports, vol. 21, no. 6, pp. 1599–1604, 2009. View at Publisher · View at Google Scholar · View at Scopus
170. R. T. Poon, C. P. Lau, J. W. Ho, W. C. Yu, S. T. Fan, and J. Wong, “Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma,” Clinical Cancer Research, vol. 9, no. 14, pp. 5339–5345, 2003. View at Scopus
171. S. Dützmann, F. Gessler, P. N. Harter et al., “The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas,” Cell Adhesion and Migration, vol. 4, no. 4, pp. 515–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
172. G. A. Hair, S. Padula, R. Zeff et al., “Tissue factor expression in human leukemic cells,” Leukemia Research, vol. 20, no. 1, pp. 1–11, 1996. View at Publisher · View at Google Scholar · View at Scopus
173. H. Wada, T. Sase, and M. Yamaguchi, “Hypercoagulant states in malignant lymphoma,” Experimental Oncology, vol. 27, no. 3, pp. 179–185, 2005. View at Scopus
174. Y. Förster, A. Meye, S. Albrecht, and B. Schwenzer, “Tissue factor and tumor: clinical and laboratory aspects,” Clinica Chimica Acta, vol. 364, no. 1-2, pp. 12–21, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
175. F. R. Rickles, “Mechanisms of cancer-induced thrombosis in cancer,” Pathophysiology of Haemostasis and Thrombosis, vol. 35, no. 1-2, pp. 103–110, 2006.
176. M. A. Kurer, “Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells,” Molecular Biology Reports, vol. 34, no. 4, pp. 221–224, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
177. M. E. Tesselaar, F. P. Romijn, I. K. Van Der Linden, F. A. Prins, R. M. Bertina, and S. Osanto, “Microparticle-associated tissue factor activity: a link between cancer and thrombosis?” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 520–527, 2007.
178. D. Garnier, C. Milsom, N. Magnus et al., “Role of the tissue factor pathway in the biology of tumor initiating cells,” Thrombosis Research, vol. 125, pp. S44–S50, 2010. View at Scopus
179. H. H. Versteeg, F. Schaffner, M. Kerver et al., “Inhibition of tissue factor signaling suppresses tumor growth,” Blood, vol. 111, no. 1, pp. 190–199, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
180. J. Rak, C. Milsom, L. May, P. Klement, and J. Yu, “Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 54–70, 2006.
181. F. Schaffner, H. H. Versteeg, A. Schillert et al., “Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development,” Blood, vol. 116, no. 26, pp. 6106–6113, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
182. A. R. Radjabi, K. Sawada, S. Jagadeeswaran et al., “Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and β1-integrin on the cell surface,” Journal of Biological Chemistry, vol. 283, no. 5, pp. 2822–2834, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
183. Y. Rong, D. E. Post, R. O. Pieper, D. L. Durden, E. G. Van Meir, and D. J. Brat, “PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma,” Cancer Research, vol. 65, no. 4, pp. 1406–1413, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
184. D. F. Altomare, M. T. Rotelli, A. Pentimone et al., “Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence,” Colorectal Disease, vol. 9, no. 2, pp. 133–138, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
185. K. Abe, M. Shoji, J. Chen et al., “Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8663–8668, 1999. View at Publisher · View at Google Scholar · View at Scopus
186. C. Li, M. E. Collier, G. A. Frentzou, J. Greenman, and C. Ettelaie, “Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity,” Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1347–1355, 2008. View at Publisher · View at Google Scholar · View at PubMed
187. W. Ruf, “Molecular regulation of blood clotting in tumor biology,” Haemostasis, vol. 31, pp. 5–7, 2001. View at Scopus
188. J. Fang, L. Gu, N. Zhu, H. Tang, C. S. Alvarado, and M. Zhou, “Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells,” BMC Cancer, vol. 8, article no. 69, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
189. H. H. Versteeg, C. A. Spek, D. J. Richel, and M. P. Peppelenbosch, “Coagulation factors VIIa and Xa inhibit apoptosis and anoikis,” Oncogene, vol. 23, no. 2, pp. 410–417, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
190. X. Jiang, Y. L. Guo, and M. E. Bromberg, “Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells,” Journal of Thrombosis and Haemostasis, vol. 96, no. 2, pp. 196–201, 2006. View at Publisher · View at Google Scholar
191. X. Jiang, S. Zhu, T. S. Panetti, and M. E. Bromberg, “Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells,” Journal of Thrombosis and Haemostasis, vol. 100, no. 1, pp. 127–133, 2008. View at Publisher · View at Google Scholar · View at PubMed
192. M. L. Nierodzik and S. Karpatkin, “Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype,” Cancer Cell, vol. 10, no. 5, pp. 355–362, 2006. View at Publisher · View at Google Scholar · View at PubMed
193. S. Dützmann, F. Gessler, P. N. Harter et al., “The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas,” Cell Adhesion and Migration, vol. 4, no. 4, pp. 515–522, 2010. View at Publisher · View at Google Scholar
194. D. Green and S. Karpatkin, “Role of thrombin as a tumor growth factor,” Cell Cycle, vol. 9, no. 4, pp. 656–661, 2010.
195. L. Hu, S. Ibrahim, C. Liu, J. Skaar, M. Pagano, and S. Karpatkin, “Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27kip1, in association with the up-regulation of skp2 and mir-222,” Cancer Research, vol. 69, no. 8, pp. 3374–3381, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
196. L. Hu, J. M. Roth, P. Brooks, J. Luty, and S. Karpatkin, “Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis,” Cancer Research, vol. 68, no. 12, pp. 4666–4673, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
197. W. Ruf and B. M. Mueller, “Thrombin generation and the pathogenesis of cancer,” Seminars in Thrombosis and Hemostasis, vol. 32, supplement 1, pp. 61–68, 2006. View at Publisher · View at Google Scholar · View at PubMed
198. F. Samad, M. Pandey, and D. J. Loskutoff, “Tissue factor gene expression in the adipose tissues of obese mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7591–7596, 1998. View at Publisher · View at Google Scholar · View at Scopus
199. F. Samad, M. Pandey, and D. J. Loskutoff, “Regulation of tissue factor gene expression in obesity,” Blood, vol. 98, no. 12, pp. 3353–3358, 2001. View at Publisher · View at Google Scholar · View at Scopus
200. K. Popko, E. Gorska, A. Stelmaszczyk-Emmel et al., “Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects,” European journal of medical research, vol. 15, supplement 2, pp. 120–122, 2010.
201. C. S. Tam, S. P. Garnett, C. T. Cowell et al., “IL-6, IL-8 and IL-10 levels in healthy weight and overweight children,” Hormone Research in Paediatrics, vol. 73, no. 2, pp. 128–134, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
202. T. Tzanavari, P. Giannogonas, and K. P. Karalis, “TNF-α and obesity,” Current Directions in Autoimmunity, vol. 11, pp. 145–156, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
203. M. E. Carr, “Diabetes mellitus: a hypercoagulable state,” Journal of Diabetes and its Complications, vol. 15, no. 1, pp. 44–54, 2001. View at Publisher · View at Google Scholar
204. M. Massi-Benedetti and M. O. Federici, “Cariovascular risk factors in type 2 diabetes: the role of hyperglycaemia,” Experimental and Clinical Endocrinology & Diabetes, vol. 107, pp. S120–S123, 1999.
205. K. Ichikawa, M. Yoshinari, M. Iwase et al., “Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients,” Atherosclerosis, vol. 136, no. 2, pp. 281–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
206. C. Ettelaie, S. Su, C. Li, and M. E. Collier, “Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells,” Microvascular Research, vol. 76, no. 3, pp. 152–160, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
207. A. J. Gerrits, C. A. Koekman, T. W. van Haeften, and J. W. Akkerman, “Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin,” Diabetes, vol. 59, no. 6, pp. 1487–1495, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
208. J. Calles-Escandon, E. Garcia-Rubi, S. Mirza, and A. Mortensen, “Type 2 diabetes: one disease, multiple cardiovascular risk factors,” Coronary Artery Disease, vol. 10, no. 1, pp. 23–30, 1999.
209. Action to Control Cardiovascular Risk in Diabetes Study Group, H. C. Gerstein, M. E. Miller, et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at PubMed
210. Advance Collaborative Group, A. Patel, S. MacMahon et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at PubMed
211. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
212. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Scopus
213. C. Garcia, B. Feve, P. Ferré et al., “Diabetes and inflammation: fundamental aspects and clinical implications,” Diabetes & Metabolism, vol. 36, no. 5, pp. 327–338, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
214. J. K. Kim, “Inflammation and insulin resistance: an old story with new ideas,” Diabetes and Metabolism Journal, vol. 34, pp. 137–145, 2010.
215. Z. Gao, A. Zuberi, M. J. Quon, Z. Dong, and J. Ye, “Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 24944–24950, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
216. A. Isada, S. Konno, N. Hizawa et al., “A functional polymorphism ($-603\text{A}\to \text{G}$) in the tissue factor gene promoter is associated with adult-onset asthma,” Journal of Human Genetics, vol. 55, no. 3, pp. 167–174, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
217. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
218. A. C. van der Wal, X. Li, and O. J. de Boer, “Tissue factor expression in the morphologic spectrum of vulnerable atherosclerotic plaques,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 40–47, 2006.
219. N. Mackman, “Role of tissue factor in hemostasis, thrombosis, and vascular development,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 6, pp. 1015–1022, 2004. View at Publisher · View at Google Scholar · View at PubMed
220. A. Celi, S. Cianchetti, G. Dell'omo, and R. Pedrinelli, “Angiotensin II, tissue factor and the thrombotic paradox of hypertension,” Expert Review of Cardiovascular Therapy, vol. 8, no. 12, pp. 1723–1729, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
221. G. Alkistis Frentzou, M. E. Collier, A. M. Seymour, and C. Ettelaie, “Differential induction of cellular proliferation, hypertrophy and apoptosis in H9c2 cardiomyocytes by exogenous tissue factor,” Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 119–130, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
222. I. Ott, “Tissue factor in acute coronary syndromes,” Seminars in Vascular Medicine, vol. 3, no. 2, pp. 185–192, 2003. View at Publisher · View at Google Scholar · View at PubMed
223. B. Jude, C. Zawadzki, S. Susen, and D. Corseaux, “Relevance of tissue factor in cardiovascular disease,” Archives des Maladies du Coeur et des Caisseaux, vol. 98, no. 6, pp. 667–671, 2005.
224. B. Freestone, A. Y. Chong, H. S. Lim, A. Blann, and G. Y. H. Lip, “Angiogenic factors in a trial fibrillation: a possible role in thrombogenesis?” Annals of Medicine, vol. 37, no. 5, pp. 365–372, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
225. J. Steffel, A. Akhmedov, H. Greutert, T. F. Lüscher, and F. C. Tanner, “Histamine induces tissue factor expression: implications for acute coronary syndromes,” Circulation, vol. 112, no. 3, pp. 341–349, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
226. D. R. Davis and J. H. Erlich, “Cardiac tissue factor: roles in physiology and fibrosis,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 3, pp. 342–348, 2008. View at Publisher · View at Google Scholar · View at PubMed
227. R. Pawlinski, A. Fernandes, B. Kehrle et al., “Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15333–15338, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
228. H. Zhou, Y. Yan, G. Xu et al., “Toll-like receptor (TLR)-4 mediates anti-${\beta }_2$GPI/${\beta }_2$GPI-induced tissue factor expression in THP-1 cells,” Clinical and Experimental Immunology, vol. 163, no. 2, pp. 189–198, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
229. I. Cavazzana, N. Manuela, C. Irene et al., “Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?” Journal of Autoimmunity, vol. 28, no. 2-3, pp. 160–164, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
230. J. Swadzba, T. Iwaniec, and J. Musial, “Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state,” Rheumatology International, vol. 31, no. 3, pp. 307–313, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
231. D. Tanne, A. Katzav, O. Beilin et al., “Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome,” Neurobiology of Disease, vol. 30, no. 1, pp. 56–64, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
232. J. Berman, G. Girardi, and J. E. Salmon, “TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss,” Journal of Immunology, vol. 174, no. 1, pp. 485–490, 2005. View at Scopus
233. P. R. Ames, I. Antinolfi, A. Ciampa et al., “Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease?” Rheumatology, vol. 47, no. 12, pp. 1832–1837, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
234. G. Girardi, “Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome,” Clinical Reviews in Allergy and Immunology, vol. 39, no. 3, pp. 160–165, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
235. P. Redecha, C. W. Franzke, W. Ruf, N. Mackman, and G. Girardi, “Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome,” Journal of Clinical Investigation, vol. 118, no. 10, pp. 3453–3461, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
236. P. Redecha, R. Tilley, M. Tencati et al., “Tissue factor: a link between C_5a and neutrophil activation in antiphospholipid antibody-induced fetal injury,” Blood, vol. 110, no. 7, pp. 2423–2431, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
237. G. Girardi, “Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice,” Journal of Reproductive Immunology, vol. 82, no. 2, pp. 126–131, 2009.
238. P. Redecha, N. van Rooijen, D. Torry, and G. Girardi, “Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury,” Blood, vol. 113, no. 17, pp. 4101–4109, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
239. J. Chen, M. Kasper, T. Heck et al., “Tissue factor as a link between wounding and tissue repair,” Diabetes, vol. 54, no. 7, pp. 2143–2154, 2005. View at Publisher · View at Google Scholar · View at Scopus
240. Z. Xu, H. Xu, V. A. Ploplis, and F. J. Castellino, “Factor VII deficiency impairs cutaneous wound healing in mice,” Molecular Medicine, vol. 16, no. 5-6, pp. 167–176, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
241. L. Holmdahl and M. L. Ivarsson, “The role of cytokines, coagulation, and fibrinolysis in peritoneal tissue repair,” European Journal of Surgery, vol. 165, no. 11, pp. 1012–1019, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
242. S. Albrecht, M. Kotzsch, C. Haller et al., “Immunological and functional analyses of the extracellular domain of human tissue factor,” Journal of Biological, vol. 379, no. 2, pp. 157–165, 1998. View at Scopus
243. G. C. Parry and N. Mackman, “Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain (TF/FVIIa-dependent extracellular protease activity is required for embryogenesis,” The Journal of Clinical Investigation, vol. 105, no. 11, pp. 1547–1554, 2000.
244. E. Melis, L. Moons, M. De Mol et al., “Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development,” Biochemical and Biophysical Research Communications, vol. 286, no. 3, pp. 580–586, 2001. View at Publisher · View at Google Scholar · View at PubMed
245. T. Luther, C. Flössel, N. Mackman et al., “Tissue factor expression during human and mouse development,” The American Journal of Pathology, vol. 149, no. 1, pp. 101–113, 1996. View at Scopus
246. B. Pedersen, T. Holscher, Y. Sato, R. Pawlinski, and N. Mackman, “A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice,” Blood, vol. 105, no. 7, pp. 2777–2782, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
247. C. Pouplard, S. Iochmann, B. Renard et al., “Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia,” Blood, vol. 97, no. 10, pp. 3300–3302, 2001. View at Publisher · View at Google Scholar · View at Scopus
248. K. Ritis, M. Doumas, D. Mastellos et al., “A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways,” Journal of Immunology, vol. 177, no. 7, pp. 4794–4802, 2006. View at Scopus
249. A. W. Rijneveld, S. Weijer, P. Bresser et al., “Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia,” Critical Care Medicine, vol. 34, no. 6, pp. 1725–1730, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
250. M. Colucci, M. R. Rossiello, A. Pentimone et al., “Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection,” Thrombosis Research, vol. 116, no. 6, pp. 471–477, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
251. N. T. Funderburg, E. Mayne, S. F. Sieg et al., “Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation,” Blood, vol. 115, no. 2, pp. 161–167, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
252. I. M. Francischetti, K. B. Seydel, R. Q. Monteiro et al., “Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes,” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 155–165, 2007. View at Publisher · View at Google Scholar · View at PubMed
253. B. S. Donahue, D. Gailani, and A. E. Mast, “Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass,” Journal of Thrombosis and Haemostasis, vol. 4, no. 5, pp. 1011–1016, 2006. View at Publisher · View at Google Scholar · View at PubMed
254. L. Moberg, “The role of the innate immunity in islet transplantation,” Upsala Journal of Medical Sciences, vol. 110, no. 1, pp. 17–55, 2005. View at Scopus
255. A. Bukovsky, C. A. Labarrere, B. Haag, C. Carter, and W. P. Faulk, “Tissue factor in normal and transplanted human kidneys,” Transplantation, vol. 54, no. 4, pp. 644–650, 1992. View at Scopus
256. M. Usui, N. Kuriyama, M. Kisawada et al., “Tissue factor expression demonstrates severe sinusoidal endothelial cell damage during rejection after living-donor liver transplantation,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 16, no. 4, pp. 513–520, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
257. F. Li, C.-H. Wang, J.-G. Wang et al., “Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet,” Journal of Thrombosis and Haemostasis, vol. 8, no. 10, pp. 2122–2132, 2010. View at Publisher · View at Google Scholar · View at PubMed
258. K. E. Brummel-Ziedins, C. Y. Vossen, S. Butenas, K. G. Mann, and F. R. Rosendaal, “Thrombin generation profiles in deep venous thrombosis,” Journal of Thrombosis and Haemostasis, vol. 3, no. 11, pp. 2497–2505, 2005. View at Publisher · View at Google Scholar · View at PubMed
259. J. Bouligand, O. Cabaret, M. Canonico, et al., “Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women,” Clinical Pharmacology & Therapeutics, vol. 89, no. 1, pp. 60–64, 2011.
260. A. Panasiuk, J. Zak, B. Panasiuk, and D. Prokopowicz, “Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis,” Blood Coagulation and Fibrinolysis, vol. 18, no. 8, pp. 739–744, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
261. N. Busso, C. Morard, R. Salvi, V. Péclat, and A. So, “Role of the tissue factor pathway in synovial inflammation,” Arthritis & Rheumatism, vol. 48, no. 3, pp. 651–659, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
262. A. Solovey, R. Kollander, A. Shet et al., “Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin,” Blood, vol. 104, no. 3, pp. 840–846, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
263. J. P. Luyendyk, K. C. Flanagan, C. D. Williams et al., “Tissue factor contributes to neutrophil CD11b expression in α-naphthylisothiocyanate-treated mice,” Toxicology and Applied Pharmacology, vol. 250, no. 3, pp. 256–262, 2011. View at Publisher · View at Google Scholar · View at PubMed
264. A. Dorfleutner, E. Hintermann, T. Tarui, Y. Takada, and W. Ruf, “Cross-talk of integrin α3β1 and tissue factor in cell migration,” Molecular Biology of the Cell, vol. 15, no. 10, pp. 4416–4425, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
265. A. Siegbahn, M. Johnell, B. B. Sorensen, L. C. Petersen, and C.-H. Heldin, “Regulation of chemotaxis by the cytoplasmic domain of tissue factor,” Journal of Thrombosis and Haemostasis, vol. 93, no. 1, pp. 27–34, 2005. View at Publisher · View at Google Scholar
266. J. Apostolopoulos, L. Moussa, and P. G. Tipping, “The cytoplasmic domain of tissue factor restricts physiological albuminuria and pathological proteinuria associated with glomerulonephritis in mice,” Nephron Experimental Nephrology, vol. 116, no. 4, pp. e72–e83, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
267. M. E. Bromberg, W. H. Konigsberg, J. F. Madison, A. Pawashe, and A. Garen, “Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 18, pp. 8205–8209, 1995. View at Publisher · View at Google Scholar · View at Scopus
268. N. Agmon-Levin, M. Blank, G. Zandman-Goddard et al., “Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 145–150, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
269. M. R. Rossiello, S. Momi, R. Caracchini et al., “A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression,” Journal of Thrombosis and Haemostasis, vol. 3, no. 11, pp. 2554–2562, 2005. View at Publisher · View at Google Scholar · View at PubMed
270. M. Matsuyama, K. Akioka, M. Okamoto, et al., “Control of renal ischemic reperfusion injury by antisense oligodeoxynuceotide of tissue factor,” Transplantation Proceedings, vol. 35, pp. 103–104, 2003.
271. A. J. Chu, T. H. Chou, and B. D. M. Chen, “Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications,” Frontiers in Bioscience, vol. 9, pp. 2697–2713, 2004.
272. X. Wang, M. Wang, M. Amarzguioui, F. Liu, Ø. Fodstad, and H. Prydz, “Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice,” International Journal of Cancer, vol. 112, no. 6, pp. 994–1002, 2004. View at Publisher · View at Google Scholar · View at PubMed
273. B. Freeman, B. A. Zehnbauer, and T. G. Buchman, “A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis,” Shock, vol. 20, no. 1, pp. 5–9, 2003.
274. D. L. Miller, K. Welty-Wolf, M. S. Carraway et al., “Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide,” American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 6, pp. 650–658, 2002.
275. F. B. Taylor, A. C. Chang, G. Peer, A. Li, M. Ezban, and U. Hedner, “Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD₁₀₀Escherichia coli,” Blood, vol. 91, no. 5, pp. 1609–1615, 1998.
276. C. S. Arnold, C. Parker, R. Upshaw et al., “The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor,” Thrombosis Research, vol. 117, no. 3, pp. 343–349, 2006. View at Publisher · View at Google Scholar · View at PubMed
277. Y. Banerjee, J. Mizuguchi, S. Iwanaga, and R. M. Kini, “Hemextin AB complex—a snake venom anticoagulant protein complex that inhibits factor VIIa activity,” Pathophysiology of Haemostasis and Thrombosis, vol. 34, no. 4-5, pp. 184–187, 2006. View at Publisher · View at Google Scholar · View at PubMed
278. S. T. Loubele, C. A. Spek, P. Leenders et al., “Active site inhibited factor VIIa attenuates myocardial ischemia/ reperfusion injury in mice,” Journal of Thrombosis and Haemostasis, vol. 7, no. 2, pp. 290–298, 2009. View at Publisher · View at Google Scholar · View at PubMed
279. P. C. Wong, J. M. Luettgen, A. R. Rendina et al., “BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies,” Journal of Thrombosis and Haemostasis, vol. 104, no. 2, pp. 261–269, 2010. View at Publisher · View at Google Scholar · View at PubMed
280. F. Ghrib, P. Léger, M. Ezban, A. J. Kristensen Cambus, and B. Boneu, “Anti-thrombotic and haemorrhagic effects of active site-inhibited factor VIIa in rats,” British Journal of Haematology, vol. 112, no. 2, pp. 506–512, 2001. View at Publisher · View at Google Scholar
281. E. I. Lev, J. D. Marmur, M. Zdravkovic et al., “Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 6, pp. 1036–1041, 2002. View at Publisher · View at Google Scholar
282. U. Ørvim, R. M. Barstad, L. Oørning et al., “Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 3049–3056, 1997.
283. D. Kirchhofer, T. B. Tschopp, and H. R. Baumgartner, “Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 8, pp. 1098–1106, 1995.
284. J. Himber, C. J. Refino, L. Burcklen, S. Roux, and D. Kirchhofer, “Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig,” Journal of Thrombosis and Haemostasis, vol. 85, no. 3, pp. 475–481, 2001.
285. L. Örning, P. M. Fischer, C.-K. Hu et al., “A cyclic pentapeptide derived from the second EGF-like domain of factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation,” Journal of Thrombosis and Haemostasis, vol. 87, no. 1, pp. 13–21, 2002.
286. J. A. Szalony, O. D. Suleymanov, A. K. Salyers et al., “Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time,” Thrombosis Research, vol. 112, no. 3, pp. 167–174, 2003. View at Publisher · View at Google Scholar · View at PubMed
287. J. Zhao, G. Aguilar, S. Palencia, E. Newton, and A. Abo, “RNAPc2 Inhibits colorectal cancer in mice through tissue factor,” Clinical Cancer Research, vol. 15, no. 1, pp. 208–216, 2009. View at Publisher · View at Google Scholar · View at PubMed
288. T. A. Hembrough, G. M. Swartz, A. Papathanassiu et al., “Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism,” Cancer Research, vol. 63, no. 11, pp. 2997–3000, 2003.
289. P. Zerbib, A. Grimonprez, D. Corseaux et al., “Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer,” Journal of Surgical Research, vol. 153, no. 2, pp. 239–245, 2009. View at Publisher · View at Google Scholar · View at PubMed
290. E. Lindmark and A. Siegbahn, “Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin,” Thrombosis Research, vol. 108, no. 1, pp. 77–84, 2002. View at Publisher · View at Google Scholar
291. K. Akahane, K. Okamoto, M. Kikuchi et al., “Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats,” Surgery, vol. 130, no. 5, pp. 809–818, 2001. View at Publisher · View at Google Scholar · View at PubMed
292. C. Viskov, M. Just, V. Laux, P. Mourier, and M. Lorenz, “Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026,” Journal of Thrombosis and Haemostasis, vol. 7, no. 7, pp. 1143–1151, 2009. View at Publisher · View at Google Scholar · View at PubMed
293. G. Lopopolo, F. Fiorella, M. de Candia et al., “Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa,” European Journal of Pharmaceutical Sciences, vol. 42, no. 3, pp. 180–191, 2011. View at Publisher · View at Google Scholar · View at PubMed
294. M. Nijkeuter and M. V. Huisman, “Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review,” Current Opinion in Pulmonary Medicine, vol. 10, no. 5, pp. 338–344, 2004.
295. D. Bergqvist, “Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes,” PharmacoEconomics, vol. 20, no. 4, pp. 225–243, 2002.
296. T. M. Chapman and K. L. Goa, “Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis,” Drugs, vol. 63, no. 21, pp. 2357–2377, 2003. View at Publisher · View at Google Scholar
297. K. Wellington, K. McClellan, and B. Jarvis, “Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism,” Drugs, vol. 61, no. 8, pp. 1185–1209, 2001.
298. A. Diquelou, D. Dupouy, R. Cariou, K. S. Sakariassen, B. Boneu, and Y. Cadroy, “A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis,” Journal of Thrombosis and Haemostasis, vol. 74, no. 5, pp. 1286–1292, 1995.
299. S. M. Cheer, C. J. Dunn, and R. Foster, “Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease,” Drugs, vol. 64, no. 13, pp. 1479–1502, 2004. View at Publisher · View at Google Scholar
300. G. F. Pineo and R. D. Hull, “Dalteparin sodium,” Expert Opinion on Pharmacotherapy, vol. 2, no. 8, pp. 1325–1337, 2001. View at Publisher · View at Google Scholar · View at PubMed
301. C. Bal dit Sollier, C. Kang, N. Berge et al., “Activity of a synthetic hexadecasaccharide(SanOrg123781A) in a pig model of arterial thrombosis,” Journal of Thrombosis and Haemostasis, vol. 2, no. 6, pp. 925–930, 2004. View at Publisher · View at Google Scholar · View at PubMed
302. M. Ragosta, L. W. Gimple, S. D. Gertz et al., “Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits,” Circulation, vol. 89, no. 3, pp. 1262–1271, 1994.
303. U. Ørvim, R. M. Barstad, G. P. Vlasuk, and K. S. Sakariassen, “Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 12, pp. 2188–2194, 1995.
304. B. Kaiser, W. Jeske, J. M. Walenga, and J. Fareed, “Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood,” Blood Coagulation and Fibrinolysis, vol. 10, no. 8, pp. 495–501, 1999.
305. T. Iba, A. Kidokoro, M. Fukunaga et al., “Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat,” Shock, vol. 17, no. 2, pp. 159–162, 2002.
306. K. Tanabe, Y. Terada, T. Shibutani, S. Kunitada, and T. Kondo, “A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor-induced disseminated intravascular coagulation in rats,” Thrombosis Research, vol. 96, no. 2, pp. 135–143, 1999. View at Publisher · View at Google Scholar
307. M. Kawamura, N. Konishi, K. Hiroe et al., “Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis,” Journal of Cardiovascular Pharmacology, vol. 56, no. 2, pp. 156–161, 2010. View at Publisher · View at Google Scholar · View at PubMed
308. T. Yokoyama, A. B. Kelly, U. M. Marzec, S. R. Hanson, S. Kunitada, and L. A. Harker, “Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates,” Circulation, vol. 92, no. 3, pp. 485–491, 1995.
309. M. U. Zafar, M. E. Farkouh, J. Osende et al., “Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients,” Journal of Thrombosis and Haemostasis, vol. 97, no. 3, pp. 487–492, 2007. View at Publisher · View at Google Scholar
310. D. R. Abendschein, P. K. Baum, D. R. Light, and J. Morser, “Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa,” Journal of Thrombosis and Haemostasis, vol. 1, no. 9, pp. 1955–1958, 2003.
311. T. B. McClanahan, G. W. Hicks, A. L. Morrison et al., “The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis,” European Journal of Pharmacology, vol. 432, no. 2-3, pp. 187–194, 2001. View at Publisher · View at Google Scholar
312. P. C. Wong, M. L. Quan, E. J. Crain, C. A. Watson, R. R. Wexler, and R. M. Knabb, “Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics,” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 351–357, 2000.
313. K. Sato, Y. Taniuchi, T. Kawasaki et al., “Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice,” Japanese Journal of Pharmacology, vol. 78, no. 2, pp. 191–197, 1998. View at Publisher · View at Google Scholar
314. S. S. Rebello, R. G. Bentley, S. R. Morgan et al., “Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis,” British Journal of Pharmacology, vol. 133, no. 7, pp. 1190–1198, 2001.
315. P. C. Wong, E. J. Crain, C. A. Watson et al., “Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 3, pp. 993–1000, 2002. View at Publisher · View at Google Scholar · View at PubMed
316. J. R. Pruitt, D. J. Pinto, M. J. Estrella et al., “Isoxazolines and isoxazoles as factor Xa inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 10, no. 8, pp. 685–689, 2000. View at Publisher · View at Google Scholar
317. J. S. Bostwick, R. Bentley, S. Morgan et al., “RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit,” Journal of Thrombosis and Haemostasis, vol. 81, no. 1, pp. 157–160, 1999.
318. M. P. Gulseth, J. Michaud, and E. A. Nutescu, “Rivaroxaban: an oral direct inhibitor of factor Xa,” American Journal of Health-System Pharmacy, vol. 65, no. 16, pp. 1520–1529, 2008. View at Publisher · View at Google Scholar · View at PubMed
319. M. A. Abboud, S. J. Needle, C. L. Burns-Kurtis et al., “Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor,” Journal of Cardiovascular Pharmacology, vol. 52, no. 1, pp. 66–71, 2008. View at Publisher · View at Google Scholar · View at PubMed
320. P. C. Wong and X. Jiang, “Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin,” Journal of Thrombosis and Haemostasis, vol. 104, no. 2, pp. 302–310, 2010. View at Publisher · View at Google Scholar · View at PubMed
321. T. Furugohri, K. Isobe, Y. Honda, et al., “DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. (new anticoagulant for the prophylaxis and treatment of thromboembolic diseases,” Journal of Thrombosis and Haemostasis, vol. 6, pp. 1542–1549, 2008.
322. B. I. Eriksson, L. Borris, O. E. Dahl, et al., “Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at PubMed
323. I. J. Banke, M. J. Arlt, M. M. Mueller et al., “Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity,” Journal of Thrombosis and Haemostasis, vol. 94, no. 5, pp. 1084–1093, 2005. View at Publisher · View at Google Scholar · View at PubMed
324. A. Amirkhosravi, S. A. Mousa, M. Amaya, and J. L. Francis, “Antimetastatic effect of tinzaparin, a low-molecular-weight heparin,” Journal of Thrombosis and Haemostasis, vol. 1, no. 9, pp. 1972–1976, 2003.
325. R. Q. Monteiro, A. R. Rezaie, J. M. Ribeiro, and I. M. Francischetti, “Ixolaris: a Factor Xa heparin-binding exosite inhibitor,” Biochemical Journal, vol. 387, no. 3, pp. 871–877, 2005. View at Publisher · View at Google Scholar · View at PubMed
326. M. Nakata, S. Kanekura, and I. Maruyama, “DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation,” Cancer Letters, vol. 122, no. 1-2, pp. 127–133, 1998. View at Publisher · View at Google Scholar
327. C. Rossi, S. Hess, R. W. Eckl, et al., “Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 lung colonies in mice,” Journal of Thrombosis and Haemostasis, vol. 4, no. 3, pp. 608–613, 2006.
328. D. J. Tyrrell, A. P. Horne, K. R. Holme, J. M. H. Preuss, and C. P. Page, “Heparin in inflammation: potential therapectic applications beyond anticoagulation,” in Advance in Pharmacology, vol. 46, pp. 151–208, Academic Press, San Diego, Calif, USA, 1999.
329. G. S. Aldea, L. O. Soltow, W. L. Chandler et al., “Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits,” Journal of Thoracic and Cardiovascular Surgery, vol. 123, no. 4, pp. 742–755, 2002. View at Publisher · View at Google Scholar
330. A. Koster, T. Fischer, M. Praus et al., “Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management,” Anesthesiology, vol. 97, no. 4, pp. 837–841, 2002.
331. G. Girardi, “Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation,” Journal of Reproductive Immunology, vol. 66, no. 1, pp. 45–51, 2005. View at Publisher · View at Google Scholar · View at PubMed
332. S. Nylander and C. Mattsson, “Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action,” Blood Coagulation and Fibrinolysis, vol. 14, no. 2, pp. 159–167, 2003. View at Publisher · View at Google Scholar
333. M. Caunt, Y. Q. Huang, P. C. Brooks, and S. Karpatkin, “Thrombin induces neoangiogenesis in the chick chorioallantoic membrane,” Journal of Thrombosis and Haemostasis, vol. 1, no. 10, pp. 2097–2102, 2003.
334. T. Arisato, K. P. Sarker, K. Kawahara et al., “The agonist of the protease-activated receptor-1 (PAR1) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human vascular smooth muscle cells,” Cellular and Molecular Life Sciences, vol. 60, no. 8, pp. 1716–1724, 2003. View at Publisher · View at Google Scholar
335. P. Jilma-Stohlawetz, C. C. Folman, A. E. von dem Borne et al., “Effects of anticoagulation on thrombopoietin release during endotoxemia,” Journal of Laboratory and Clinical Medicine, vol. 137, no. 1, pp. 64–69, 2001. View at Publisher · View at Google Scholar · View at PubMed
336. K. G. Fischer, “The role of recombinant hirudins in the management of thrombotic disorders,” BioDrugs, vol. 18, no. 4, pp. 235–268, 2004. View at Publisher · View at Google Scholar
337. W. E. Dager, T. G. Vondracek, B. A. McIntosh, and E. A. Nutescu, “Ximelagatran: an oral direct thrombin inhibitor,” Annals of Pharmacotherapy, vol. 38, no. 11, pp. 1881–1897, 2004. View at Publisher · View at Google Scholar · View at PubMed
338. J. Fareed and W. P. Jeske, “Small-molecule direct antithrombins: argatroban,” Best Practice & Research: Clinical Haematology, vol. 17, no. 1, pp. 127–138, 2004. View at Publisher · View at Google Scholar · View at PubMed
339. G. Vogel, M. D. G. Meuleman, T. G. Van Dinther, R. Buijsman, A. W. Princen, and M. J. Smit, “Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity,” Journal of Thrombosis and Haemostasis, vol. 1, no. 9, pp. 1945–1954, 2003.
340. M. T. Nieman, F. Burke, M. Warnock, et al., “Thrombostatin FM-19 compounds: direct thrombin inhibitors—mechanism of action in vitro and in vivo,” Journal of Thrombosis and Haemostasis, vol. 6, no. 5, pp. 837–845, 2008.
341. M. T. Nieman, G. A. LaRusch, C. Fang, Y. Zhou, and A. H. Schmaier, “Oral thrombostatin FM19 inhibits prostate cancer,” Journal of Thrombosis and Haemostasis, vol. 104, no. 5, pp. 1044–1048, 2010. View at Publisher · View at Google Scholar · View at PubMed
342. K. Asanuma, H. Wakabayashi, T. Hayashi et al., “Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis,” Oncology, vol. 67, no. 2, pp. 166–173, 2004. View at Publisher · View at Google Scholar · View at PubMed
343. M. Ohkoshi and Y. Sasaki, “Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan),” In Vivo, vol. 19, no. 1, pp. 133–136, 2005.
344. K. DeFeo, C. Hayes, M. Chernick, J. V. Ryn, and S. K. Gilmour, “Use of dabigatran etexilate to reduce breast cancer progression,” Cancer Biology and Therapy, vol. 10, no. 10, pp. 1001–1008, 2010. View at Publisher · View at Google Scholar · View at PubMed
345. A. A. Creasey, A. C. Chang, L. Fiegen, T. C. Wun, F. B. Taylor, and L. B. Hinshaw, “Tissue factor pathway inhibitor reduces mortality from E. Coli septic shock,” The Journal of Clinical Investigation, vol. 91, pp. 2850–2860, 1993.
346. K. Johnson, L. Aarden, Y. Choi, E. De Groot, and A. Creasey, “The proinflammatory cytokine response to coagulation and endotoxin in whole blood,” Blood, vol. 87, no. 12, pp. 5051–5060, 1996.
347. D. Chen, K. Riesbeck, J. H. McVey et al., “Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins,” Xenotransplantation, vol. 8, no. 4, pp. 258–265, 2001. View at Publisher · View at Google Scholar
348. C. T. Park, A. A. Creasey, and S. D. Wright, “Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14,” Blood, vol. 89, no. 12, pp. 4268–4274, 1997.
349. C. W. Kopp, T. Hölzenbein, S. Steiner et al., “Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity,” Blood, vol. 103, no. 5, pp. 1653–1661, 2004. View at Publisher · View at Google Scholar · View at PubMed
350. P. F. Laterre, “Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition,” Critical Care, vol. 12, no. 6, article no. S4, 2008. View at Publisher · View at Google Scholar · View at PubMed
351. N. Kijiyama, H. Ueno, I. Sugimoto et al., “Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis,” Biochemical and Biophysical Research Communications, vol. 339, no. 4, pp. 1113–1119, 2006. View at Publisher · View at Google Scholar · View at PubMed
352. L. J. Toltl, L. L. Swystun, L. Pepler, and P. C. Liaw, “Protective effects of activated protein C in sepsis,” Journal of Thrombosis and Haemostasis, vol. 100, no. 4, pp. 582–592, 2008. View at Publisher · View at Google Scholar
353. P. P. Sarangi, H. W. Lee, and M. Kim, “Activated protein C action in inflammation,” British Journal of Haematology, vol. 148, no. 6, pp. 817–833, 2010. View at Publisher · View at Google Scholar · View at PubMed
354. B. White, M. Schmidt, C. Murrph, et al., “Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor α (TNF-κ) production in the THP-1 moncytic cell line,” British Journal of Haematology, vol. 110, no. 1, pp. 130–134, 2000.
355. M. Nimah and R. J. Brilli, “Coagulation dysfunction in sepsis and multiple organ system failure,” Critical Care Clinics, vol. 19, no. 3, pp. 441–458, 2003. View at Publisher · View at Google Scholar
356. D. E. Joyce and B. W. Grinnell, “Recombinant human activated protein C attunates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB,” Critical Care Medicine, vol. 30, pp. S288–S293, 2002.
357. A. Mansell, A. Reinicke, D. M. Worrall, and L. A. O'Neill, “The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-κB activation by TLR-4,” FEBS Letters, vol. 508, no. 3, pp. 313–317, 2001.
358. H. Isobe, K. Okajima, M. Uchiba, N. Harada, and H. Okabe, “Antithrombin prevents endotoxin-induced hyptension by inhibiting the induction of nitric oxide synthesis in rats,” Blood, vol. 99, pp. 1638–1645, 2002. View at Publisher · View at Google Scholar
359. M. C. Minnema, A. C. K. Chang, P. M. Jansen, et al., “Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with E. Coli,” Blood, vol. 95, pp. 1117–1123, 2000.
360. B. L. Warren, A. Eid, P. Singer, et al., “Caring for the critically ill patients. High-dose antithrombin III in severe sepsis: a randomized controlled trial,” Journal of the American Medical Association, vol. 286, pp. 1869–1878, 2001.
361. A. K. Lindahl, P. M. Sandset, M. Thune-Wiiger, O. Nordfang, and K. S. Sakariassen, “Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix,” Blood Coagulation and Fibrinolysis, vol. 5, no. 5, pp. 755–760, 1994.
362. J. Holst, B. Lindblad, D. Bergqvist et al., “Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis: a comparison with low molecular weight heparin,” Journal of Thrombosis and Haemostasis, vol. 71, no. 2, pp. 214–219, 1994.
363. D. R. Sheppard, “Activated protein C resistance: the most common risk factor for venous thromboembolism,” Journal of the American Board of Family Practice, vol. 13, no. 2, pp. 111–115, 2000.
364. M. Bhattacharyya, M. Kannan, V. P. Chaudhry, and R. Saxena, “Venous thrombosis: prevalence of prothrombotic defects in north Indian population,” Indian Journal of Pathology and Microbiology, vol. 46, no. 4, pp. 621–624, 2003.
365. F. España, A. Vayá, Y. Mira et al., “Low level of circulating activated protein C is a risk factor for venous thromboembolism,” Journal of Thrombosis and Haemostasis, vol. 86, no. 6, pp. 1368–1373, 2001.
366. T. Urano, F. J. Castellino, H. Ihara et al., “Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1,” Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2615–2620, 2003.
367. L. Bajzar, M. E. Nesheim, and P. B. Tracy, “The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent,” Blood, vol. 88, no. 6, pp. 2093–2100, 1996.
368. C. V. Jackson, B. D. Bailey, and T. J. Shetler, “Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 3, pp. 967–971, 2000.
369. Y. Aoki, Y. Fukumoto, K. Inoue, Y. Katsuura, K. Komoriya, and S. Miyamoto, “Effect of activated human protein C on experimental venous thrombosis induced by stasis with operative invasion in mice,” Arzneimittel-Forschung, vol. 50, no. 8, pp. 695–699, 2000.
370. K. D. Kurz, T. Smith, A. Wilson, B. Gerlitz, M. A. Richardson, and B. W. Grinnell, “Antithrombotic efficacy in the guinea pig of a derivative of human protein C with enhanced activation by thrombin,” Blood, vol. 89, no. 2, pp. 534–540, 1997.
371. H. Araki, K. Nishi, N. Ishihara, and K. Okajima, “Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries,” Thrombosis Research, vol. 62, no. 3, pp. 209–216, 1991. View at Publisher · View at Google Scholar
372. A. Gruber, S. R. Hanson, A. B. Kelly et al., “Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis,” Circulation, vol. 82, no. 2, pp. 578–585, 1990.
373. K. Malm, B. Dahlbäck, and B. Arnljots, “Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S,” Journal of Thrombosis and Haemostasis, vol. 90, no. 2, pp. 227–234, 2003.
374. B. Arnljots, D. Bergqvist, and B. Dahlback, “Inhibition of microarterial thrombosis by activated protein C in a rabbit model,” Journal of Thrombosis and Haemostasis, vol. 72, no. 3, pp. 415–420, 1994.
375. R. S. Foo, A. H. Gershlick, K. Hogrefe et al., “Inhibition of platelet thrombosis using an activated protein C-loaded stent: In vitro and in vivo results,” Journal of Thrombosis and Haemostasis, vol. 83, no. 3, pp. 496–502, 2000.
376. L. Ostrovsky, R. C. Woodman, D. Payne, D. Teoh, and P. Kubes, “Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion,” Circulation, vol. 96, no. 7, pp. 2302–2310, 1997.
377. Y.-F. Lin, N. Zhang, H.-S. Guo et al., “Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway,” Apoptosis, vol. 12, no. 12, pp. 2163–2173, 2007. View at Publisher · View at Google Scholar · View at PubMed
378. E. Sierko, M. Z. Wojtukiewicz, and W. Kisiel, “The role of tissue factor pathway inhibitor-2 in cancer biology,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 7, pp. 653–659, 2007. View at Publisher · View at Google Scholar · View at PubMed
379. M. Kurata, K. Okajima, T. Kawamoto, M. Uchiba, and N. Ohkohchi, “Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells,” World Journal of Gastroenterology, vol. 12, no. 1, pp. 60–65, 2006.
380. M. S. O'Reilly, “Antiangiogenic antithrombin,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 7, pp. 660–666, 2007. View at Publisher · View at Google Scholar · View at PubMed
381. G. L. van Sluis, H. R. Büller, and C. A. Spek, “The role of activated protein C in cancer progression,” Thrombosis research, vol. 125, supplement 2, pp. S138–142, 2010.
382. M. Bezuhly, R. Cullen, C. T. Esmon et al., “Role of activated protein C and its receptor in inhibition of tumor metastasis,” Blood, vol. 113, no. 14, pp. 3371–3374, 2009. View at Publisher · View at Google Scholar · View at PubMed
383. C. K. Derian, B. P. Damiano, M. F. Addo et al., “Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 2, pp. 855–861, 2003. View at Publisher · View at Google Scholar · View at PubMed
384. C.-C. Wu and C.-M. Teng, “Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation,” European Journal of Pharmacology, vol. 546, no. 1-3, pp. 142–147, 2006. View at Publisher · View at Google Scholar · View at PubMed
385. H.-S. Ahn, C. Foster, G. Boykow, A. Stamford, M. Manna, and M. Graziano, “Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1- methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist,” Biochemical Pharmacology, vol. 60, no. 10, pp. 1425–1434, 2000. View at Publisher · View at Google Scholar
386. L. Ma, R. Perini, W. McKnight et al., “Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 216–220, 2005. View at Publisher · View at Google Scholar · View at PubMed
387. J. L. Strande, A. Hsu, J. Su, X. Fu, G. J. Gross, and J. E. Baker, “SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts,” Basic Research in Cardiology, vol. 102, no. 4, pp. 350–358, 2007. View at Publisher · View at Google Scholar · View at PubMed
388. N. Kamio, H. Hashizume, S. Nakao, K. Matsushima, and H. Sugiya, “Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp,” Biochemical Pharmacology, vol. 75, no. 10, pp. 1974–1980, 2008. View at Publisher · View at Google Scholar · View at PubMed
389. S. Chackalamannil, Y. Wang, W. J. Greenlee et al., “Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity,” Journal of Medicinal Chemistry, vol. 51, no. 11, pp. 3061–3064, 2008. View at Publisher · View at Google Scholar · View at PubMed
390. R. Colognato, J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet, “Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells,” Blood, vol. 102, no. 7, pp. 2645–2652, 2003. View at Publisher · View at Google Scholar · View at PubMed
391. J. T. Elliott, W. J. Hoekstra, B. E. Maryanoff, and G. D. Prestwich, “Photoactivatable peptides based on BMS-197525: a potent antagonist of the human thrombin receptor (PAR-1),” Bioorganic and Medicinal Chemistry Letters, vol. 9, no. 2, pp. 279–284, 1999. View at Publisher · View at Google Scholar
392. M. S. Bernatowicz, C. E. Klimas, K. S. Hartl, M. Peluso, N. J. Allegretto, and S. M. Seiler, “Development of potent thrombin receptor antagonist peptides,” Journal of Medicinal Chemistry, vol. 39, no. 25, pp. 4879–4887, 1996. View at Publisher · View at Google Scholar · View at PubMed
393. Y. Kato, Y. Kita, Y. Hirasawa-Taniyama et al., “Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig,” European Journal of Pharmacology, vol. 473, no. 2-3, pp. 163–169, 2003. View at Publisher · View at Google Scholar
394. M. T. Nieman, M. Warnock, A. A. Hasan et al., “The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, pp. 492–501, 2004. View at Publisher · View at Google Scholar · View at PubMed
395. N. Cenac, C. N. Andrews, M. Holzhausen et al., “Role for protease activity in visceral pain in irritable bowel syndrome,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 636–647, 2007. View at Publisher · View at Google Scholar · View at PubMed
396. S. H. Slofstra, M. F. Bijlsma, A. P. Groot et al., “Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation,” Blood, vol. 110, no. 9, pp. 3176–3182, 2007. View at Publisher · View at Google Scholar · View at PubMed
397. C.-C. Wu, T.-L. Hwang, C.-H. Liao et al., “Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-₃,” Journal of Thrombosis and Haemostasis, vol. 87, no. 6, pp. 1026–1033, 2002.
398. J. L. Strande, A. Hsu, J. Su, X. Fu, G. J. Gross, and J. E. Baker, “Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 1045–1054, 2008. View at Publisher · View at Google Scholar · View at PubMed
399. A. J. Leger, S. L. Jacques, J. Badar et al., “Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis,” Circulation, vol. 113, no. 9, pp. 1244–1254, 2006. View at Publisher · View at Google Scholar · View at PubMed
400. R. Colognato, J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet, “Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells,” Blood, vol. 102, no. 7, pp. 2645–2652, 2003. View at Publisher · View at Google Scholar · View at PubMed
401. N. Roche, R. G. Stirling, S. Lim, B. G. Oliver, and K. F. Chung, “Regulation of protease-activated receptor-I in mononuclear cells by neutrophil proteases,” Respiratory Medicine, vol. 97, no. 3, pp. 228–233, 2003. View at Publisher · View at Google Scholar
402. S. Dulon, C. Candé, N. W. Bunnett, M. D. Hollenberg, M. Chignard, and D. Pidard, “Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 3, pp. 339–346, 2003. View at Publisher · View at Google Scholar
403. G. S. Cottrell, S. Amadesi, F. Schmidlin, and N. Bunnett, “Protease-activated receptor 2: activation, signalling and function,” Biochemical Society Transactions, vol. 31, no. 6, pp. 1191–1197, 2003.
404. M. Tang, G. Wang, P. Lu et al., “Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure,” Nature Medicine, vol. 9, no. 12, pp. 1506–1512, 2003. View at Publisher · View at Google Scholar · View at PubMed
405. A. Silini, C. Ghilardi, C. Ardinghi et al., “Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype,” Clinical and Experimental Metastasis, vol. 27, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at PubMed
406. L. Ma, R. Perini, W. McKnight et al., “Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 216–220, 2005. View at Publisher · View at Google Scholar · View at PubMed
407. L.-H. Chang, C.-H. Chen, D.-Y. Huang, H.-C. Pai, S.-L. Pan, and C.-M. Teng, “Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells,” Journal of Cellular Physiology, vol. 226, no. 4, pp. 1060–1068, 2011. View at Publisher · View at Google Scholar · View at PubMed
408. A. B. Pawashe, P. Golino, G. Ambrosio et al., “A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries,” Circulation Research, vol. 74, no. 1, pp. 56–63, 1994.
409. J. Himber, C. Wohlgensinger, S. Roux, et al., “Inhibition of tissue factor limits the growth of venous thrombus in the rabbit,” Journal of Thrombosis and Haemostasis, vol. 1, pp. 889–895, 2003.
410. C. C. Milsom, J. L. Yu, N. Mackman et al., “Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis,” Cancer Research, vol. 68, no. 24, pp. 10068–10076, 2008. View at Publisher · View at Google Scholar · View at PubMed
411. D. M. Berman, O. Cabrera, N. M. Kenyon et al., “Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model,” Transplantation, vol. 84, no. 3, pp. 308–315, 2007. View at Publisher · View at Google Scholar · View at PubMed
412. F. W. Eichbaum, O. Slemer, and S. B. Zyngier, “Anti-inflammatory effect of warfarin and vitamin K1,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 307, no. 2, pp. 185–190, 1979.
413. P. S. Maclean, R. C. Tait, A. Rumley, A. D. McMahon, and G. D. Lowe, “Anticoagulation with warfarin downregulates inflammation,” Journal of Thrombosis and Haemostasis, vol. 1, no. 8, pp. 1838–1839, 2003.
414. V. Pengo, G. Denas, S. P. Jose, and M. F. Pengo, “Cancer prevention and vitamin K antagonists: an overview,” Thrombosis Research, vol. 125, pp. S103–S105, 2010.
415. S. Del Turco, G. Basta, G. Lazzerini et al., “Parallel decrease of tissue factor surface exposure and increase of tissue factor microparticle release by the n-3 fatty acid docosahexaenoate in endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 98, no. 1, pp. 210–219, 2007. View at Publisher · View at Google Scholar
416. A. J. Chu, “Blood coagulation fuels inflammation implementing a blood coagulation-inflammation-thrombosis Circuit,” in Handbook of Hematology Research, R. Tondre and C. Lebegue, Eds., Chapter 2, pp. 33–86, Nova Science, 2010.
417. C. Jin and R. A. Flavell, “Molecular mechanism of NLRP3 inflammasome activation,” Journal of Clinical Immunology, vol. 30, no. 5, pp. 628–631, 2010. View at Publisher · View at Google Scholar · View at PubMed
418. D. J. Taxman, M. T. Huang, and J. P. Ting, “Inflammasome inhibition as a pathogenic stealth mechanism,” Cell Host & Microbe, vol. 8, no. 1, pp. 7–11, 2010.
419. T. D. Kanneganti, “Central roles of NLRs and inflammasomes in viral infection,” Nature Reviews Immunology, vol. 10, no. 10, pp. 688–698, 2010. View at Publisher · View at Google Scholar · View at PubMed
420. S. Joly and F. S. Sutterwala, “Fungal pathogen recognition by the NLRP3 inflammasome,” Virulence, vol. 1, no. 4, pp. 276–280, 2010.
421. I. K. Pang and A. Iwasaki, “Inflammasomes as mediators of immunity against influenza virus,” Trends in Immunology, vol. 32, no. 1, pp. 34–41, 2011. View at Publisher · View at Google Scholar · View at PubMed
422. L. Franchi, R. Muñoz-Planillo, T. Reimer, T. Eigenbrod, and G. Núñez, “Inflammasomes as microbial sensors,” European Journal of Immunology, vol. 40, no. 3, pp. 611–615, 2010. View at Publisher · View at Google Scholar · View at PubMed
423. P. Duewell, H. Kono, K. J. Rayner et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, vol. 464, no. 7293, pp. 1357–1361, 2010. View at Publisher · View at Google Scholar · View at PubMed
424. F. Martinon, “Mechanisms of uric acid crystal-mediated autoinflammation,” Immunological Reviews, vol. 233, no. 1, pp. 218–232, 2010. View at Publisher · View at Google Scholar · View at PubMed
425. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp, “Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, vol. 320, no. 5876, pp. 674–677, 2008. View at Publisher · View at Google Scholar · View at PubMed
426. B. K. Davis, H. Wen, and J. P. Ting, “The Inflammasome NLRs in immunity, inflammation, and associated diseases,” Annual Review of Immunology, vol. 29, pp. 707–735, 2011. View at Publisher · View at Google Scholar · View at PubMed
427. A. J. Chu, “Biochemical strategies to anticoagulation: a comparative overview,” Current Vascular Pharmacology, vol. 2, no. 3, pp. 199–228, 2004. View at Publisher · View at Google Scholar